Knock down of SMYD3 in ovarian cancer tissues leads to upregulation of CDKN2B (p15INK4B), CDKN2A (p16INK4), CDC25A and CDKN3 as members of cyclin-dependent kinase inhibitors (CDK) [24]. This evidence concerns the gene CDKN2B and ovarian carcinoma.